We are evaluating competing offers between a strategic competitor offering a higher multiple and a private equity sponsor offering a lower multiple with equity upside. How do we objectively compare the real execution risk and net proceeds between strategic and financial buyers?

Question

Tyler Smith · Accepted Answer

A high headline multiple from a strategic competitor often hides significant execution friction, while a lower multiple from a private equity firm may offer higher closing certainty and valuable secondary upside. Evaluating competing bids requires you to look beyond enterprise value and assess execution risk, integration realities, and capital timing.

Strategic buyers pay for commercial and operational synergies. They can justify higher multiples because they plan to absorb your accounts and eliminate redundant overhead, often including your leadership team. However, strategic diligence introduces intense risks:

- They request deep operational data, customer lists, and pricing margins that could damage your competitive standing if the transaction collapses.
- Strategic deals face higher regulatory scrutiny, longer closing timelines, and complex culture integration hurdles that often delay full payouts.

Financial sponsors, such as private equity groups, value existing execution engines. If your business runs smoothly with clear roles on the Accountability Chart and disciplined quarterly execution, sponsors back the management team and support scalable acquisitions. Their advantages include:

- A faster, cleaner diligence path focused almost entirely on financial integrity and market tailwinds.
- Transaction structures that typically leave your operational culture intact.
- An opportunity to participate in a second bite of the apple via rollover equity, which can yield substantial upside on their subsequent sale.

Model both bids on a net after-tax, risk-adjusted basis. Factor in the cost of failed diligence with a competitor against the compounding potential of sponsor-backed growth.